Beranda › Kanker Metastatik › Texas › Abilene
Uji klinis Kanker Metastatik di Abilene, TX
5 studi untuk Kanker Metastatik mencari peserta di lokasi sekitar Abilene (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Menerima pesertaFase 2
- Hendrick Medical Center, Abilene
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Menerima pesertaFase 3
- Texas Oncology - West Texas, Abilene
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Menerima pesertaFase 3
- Texas Oncology - West Texas, Abilene
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Menerima pesertaFase 3
- Texas Oncology - West Texas, Abilene
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Menerima pesertaFase 3
- Hendrick Medical Center, Abilene
Uji klinis Kanker Metastatik di kota lain
- Houston, TX104 studi
- New York City, NY93 studi
- Nashville, TN70 studi
- Boston, MA63 studi
- Los Angeles, CA57 studi
- St. Louis, MO54 studi
- Arlington, VA53 studi
- Philadelphia, PA46 studi
- Chicago, IL45 studi
- San Antonio, TX44 studi
- Washington, DC43 studi
- Dallas, TX42 studi
Studi lain di Abilene
- Kanker Paru Non-Sel Kecil8 studi
- Kanker Payudara5 studi
- Kanker Kolorektal5 studi
- Kanker Ovarium4 studi
- Degenerasi Makula4 studi
- Kanker Payudara Triple-Negatif3 studi
- Atrofi Geografis3 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.